Neumora Therapeutics (NMRA) Non-cash Items (2022 - 2026)

Neumora Therapeutics has reported Non-cash Items for 5 years, with the latest figure at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items rose 61.19% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (up 61.19% YoY), and the FY2025 full-year result was $2.7 million, down 93.97% from the prior year.
• Non-cash Items for Q1 2026 stood at $10.5 million, up from $2.7 million in the prior quarter.
• The five-year high for Non-cash Items was $147.0 million in Q4 2023, with the low at $2.7 million in Q4 2025.
• Average Non-cash Items over 5 years is $29.4 million, with a median of $7.4 million recorded in 2025.
• Year-over-year, Non-cash Items jumped 510.2% in 2023 and tumbled 93.97% in 2025.
• Tracing NMRA's Non-cash Items over 5 years: stood at $24.1 million in 2022, then jumped by 510.2% to $147.0 million in 2023, then plunged by 69.41% to $45.0 million in 2024, then plunged by 93.97% to $2.7 million in 2025, then surged by 286.01% to $10.5 million in 2026.
• The last three Non-cash Items figures came in at $10.5 million (Q1 2026), $2.7 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.

Peer Comparison